Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)

Compare
10.68
+0.17
+(1.62%)
At close: 3:00:00 PM GMT+8
Loading Chart for 603567.SS
  • Previous Close 10.51
  • Open 10.51
  • Bid 10.68 x --
  • Ask 10.69 x --
  • Day's Range 10.40 - 10.68
  • 52 Week Range 9.81 - 13.63
  • Volume 4,436,964
  • Avg. Volume 4,927,983
  • Market Cap (intraday) 10.051B
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 15.04
  • EPS (TTM) 0.71
  • Earnings Date --
  • Forward Dividend & Yield 0.20 (1.90%)
  • Ex-Dividend Date Jul 12, 2024
  • 1y Target Est --

Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.

www.zbdzy.com

2,545

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603567.SS

View More

Performance Overview: 603567.SS

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603567.SS
7.93%
SSE Composite Index (000001.SS)
2.24%

1-Year Return

603567.SS
1.94%
SSE Composite Index (000001.SS)
6.59%

3-Year Return

603567.SS
26.45%
SSE Composite Index (000001.SS)
2.54%

5-Year Return

603567.SS
9.57%
SSE Composite Index (000001.SS)
15.44%

Compare To: 603567.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603567.SS

View More

Valuation Measures

Annual
As of 4/18/2025
  • Market Cap

    10.05B

  • Enterprise Value

    12.45B

  • Trailing P/E

    15.38

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.22

  • Price/Book (mrq)

    1.30

  • Enterprise Value/Revenue

    3.99

  • Enterprise Value/EBITDA

    15.26

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.96%

  • Return on Assets (ttm)

    3.55%

  • Return on Equity (ttm)

    8.31%

  • Revenue (ttm)

    3.12B

  • Net Income Avi to Common (ttm)

    653.39M

  • Diluted EPS (ttm)

    0.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    966.16M

  • Total Debt/Equity (mrq)

    40.54%

  • Levered Free Cash Flow (ttm)

    -597.32M

Research Analysis: 603567.SS

View More

Company Insights: 603567.SS

Research Reports: 603567.SS

View More

People Also Watch